Mustang Bio Inc's Comment on Sales, Marketing and Customers
The company, a majority-controlled subsidiary of Fortress Biotech, Inc., has not generated any product sales and has incurred substantial operating losses. Its therapeutic pipeline includes MB-109, a combination of MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma) and MB-108 (HSV-1 oncolytic virus C134), targeting IL13Rα2-positive relapsed or refractory glioblastoma and high-grade astrocytoma. This approach utilizes adoptive cellular immunotherapy with CAR T cells and oncolytic viruses to kill cancer cells and modify the tumor microenvironment. Preclinical studies conducted by investigators from City of Hope, including Dr. Christine Brown, demonstrated that the combination therapy reshapes the tumor microenvironment and enhances CAR T cell therapy efficacy without additional adverse events, supporting its potential benefit for glioblastoma treatment.
Mustang Bio, a pioneer in cell and gene therapies for life-threatening diseases, recently declared its strategic plan for expanding the CAR T-cell therapy platform into the realm of autoimmune diseases. This divergent approach is commendably progressive, envisaging the broad therapeutic potential of CAR T-cell technology beyond its typical oncology applications.The company is prepping for a proof-of-concept Phase 1 investigator-sponsored clinical trial, directed at evaluating the effects of MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases. Marked to initiate in the fourth quarter of 2024, the trial provides a promising endeavor in carving out novel treatment modalities for the management of aut...
Mustang Bio Inc’s Comment on Sales, Marketing and Customers
The company, a majority-controlled subsidiary of Fortress Biotech, Inc., has not generated any product sales and has incurred substantial operating losses. Its therapeutic pipeline includes MB-109, a combination of MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma) and MB-108 (HSV-1 oncolytic virus C134), targeting IL13Rα2-positive relapsed or refractory glioblastoma and high-grade astrocytoma. This approach utilizes adoptive cellular immunotherapy with CAR T cells and oncolytic viruses to kill cancer cells and modify the tumor microenvironment. Preclinical studies conducted by investigators from City of Hope, including Dr. Christine Brown, demonstrated that the combination therapy reshapes the tumor microenvironment and enhances CAR T cell therapy efficacy without additional adverse events, supporting its potential benefit for glioblastoma treatment.
Sources:
Mustang Bio inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Mustang Bio inc’s corporate clients.
For your research, we’ve provided 9 tables on Mustang Bio inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
